4 billion large varieties of Huahai into the game against the third batch of collection.

Today (June 30), NMPA official website shows that Huahai Pharmaceutical sau-ping collapse tablets were approved for listing, the approval number for the National Drug Code H20203281, the National Drug Code H20203282According to Minnet.com, sales of the terminal of China's public medical institutions in 2019 exceeded 4 billion yuanHuahai Pharmaceuticals' O Nitrogen Flat-pass collapse piece for the fourth domestic review, the variety of market competition will be further upgradedIsaipine is the first atypical antipsychotic drug approved for long-term treatment of schizophrenia and the first atypical antipsychotic drug approved to treat acute bipolar maniaDomestic listed O Nitrogen ping products have Ao nitrogen flat tablets, Au nitrogen flat-mouth collapse tablets, Au nitrogen flat sheet for the first batch of varieties, Au nitrogen flat-mouth edified tablets for the third batch of proposed collection varietiesaccording to-meter net, sales of end-terminals in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) exceeded 4 billion yuan in 2019, up 4.17 percent year-on-yearAmong them, Howson Pharmaceuticals accounted for 63.9 percent of the market, DrReddy of India accounted for 18.21 percent and Lilly 15.57 percentchina's public medical institutions terminal O Nitrogen Ping sales situation (units: 10,000 yuan)within the network consistency evaluation database shows that Qilu Pharmaceuticals, Dongsun Pharmaceuticals, Hausen Pharmaceuticals' Au nitrogen flat collapse tablets have passed the consistency evaluationHuahai Pharmaceuticals' O-Nitrogen flat-mouth collapse film according to imitation 4 categories of production, as the same through consistency evaluation, the market competition of this species will be further upgradedpreviously commented on theof the company.